Nov. 10 at 3:12 PM
$CRBU $VERV $LLY $PSTX Lilly watched Verve for two years after a
$60M partnership before buying it for
$1.3B. The playbook is the same. Pfizer invested
$25M into Caribou in July 2023, took a board seat, and holds ROFN rights through July 2026. They have had full visibility into the data since day one. Caribou just delivered clean 12 month CRs and strong safety, the proof point Pfizer needed. The reverse split was canceled, burn is reduced, and cash covers the runway into 2026. Pfizer is not in a hurry. They are letting the setup ripen while maintaining control from the inside.
Roche did this exact same thing with Poseida. First came a collaboration, then a quiet year of watching data mature, followed by a full
$1.5B acquisition once durability and safety were proven. Pfizer’s pattern with Caribou is identical, only with deeper access and longer visibility. Every move points to preparation, not survival. The structure, timing, and silence all signal a buyout in progress.
